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References: 9 55 
Capsule summary 56 
Reanalysis of UK22 subcutaneous immunotherapy trial according to WAO/EAACI 57 
recommendations revealed clinically relevant improvements at both doses. Starting at the lower 58 
dose should enable efficacy with lower risk of adverse events. 59 
Key words: Subcutaneous allergen immunotherapy, grass pollen immunotherapy, combined 60 
symptom and medication score, allergic rhinitis.  61 
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To the Editor: 63 
Subcutaneous immunotherapy (SCIT) is widely used for therapy of patients with allergic 64 
rhinoconjunctivitis, with or without allergic asthma [1-3]. The strength of clinical evidence 65 
supporting this treatment varies between different allergen immunotherapy (AIT) products. In 66 
addition AIT products are not directly comparable as they differ in allergen content, allergen 67 
structure (chemically modified allergens/intact allergens), adjuvants used or application 68 
formulations. Consequently, clinical efficacy must be documented individually for each product 69 
[2,3].  70 
The efficacy of Alutard SQ® Phleum pratense (ALK, Denmark) for allergen immunotherapy for 71 
grass pollen allergic patients has been demonstrated in several controlled clinical trials with adults 72 
and children [4-7], both with the maximum dose for maintenance treatment 100,000 SQ-U, and 73 
also with a lower dose of 10,000 SQ-U [4]. Supplementary references on clinical trials with the 74 
product and identical manufactured products can be found in the online repository. 75 
In a large randomized, double blind, placebo-controlled clinical trial in 26 UK hospital clinics 76 
conducted in 2002, the UK22 trial, subjects were randomized in a 1:1:2 ratio to receive placebo, 77 
Alutard SQ Phleum pratense 10,000 SQ-U or 100,000 SQ-U as maintenance dose. Details of 78 
inclusion and exclusion criteria, subject characteristics, dosage schedules and the individual 79 
primary and secondary outcome parameters have been published previously [4]. As (co-)primary 80 
endpoints symptom scores and medication use were evaluated separately. While the symptom 81 
scores were significantly lower compared with placebo for both doses, the medication scores were 82 
statistically significantly decreased only with the higher dose (100,000 SQ-U). Responders to AIT 83 
were 76.7% of subjects with 100,000 SQ-U, 66.3% with 10,000 SQ-U and 55.0% with placebo 84 
according to subjective evaluations of symptoms (subjects who reported improvement compared to 85 
previous years, see Table 1 in the Online repository). There was a clear dose-dependent effect 86 
on the responder rate – the surprisingly high placebo responder rate was likely a result of the 87 
participant’s free and open access to usual anti-allergic drugs, such that all 3 groups responded. 88 
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The tolerability of treatment was also dose-dependent, with fewer adverse events on the 10,000 89 
SQ-U maintenance dose, although local and delayed side effects were generally mild. Clinically 90 
significant early and delayed systemic side effects were confined to the 100,000 SQ-U group. In 91 
this group urticaria or asthma graded as early non-life threatening grade 3 reactions according to 92 
the European Academy of Allergy and Clinical Immunology (EAACI) grading scheme were 93 
reported in 4.4% of subjects, and urticaria, wheezing, asthma and angioedema as delayed 94 
systemic reactions graded mild in 14% of subjects and severe in 2% [4]. This is in line with results 95 
from other trials with the 100,000 SQ-U maintenance dose [5-7]. 96 
After completion of the UK22 trial a World Allergy Organization (WAO) task force [8] recommended 97 
to combine symptom scores and medication scores as key primary endpoints in AIT trials, and in a 98 
recent Position Paper of the EAACI, [9] a consensus definition for the combined symptom and 99 
medication score (CSMS) has been published. The CSMS used as the primary outcome parameter 100 
for efficacy in clinical trials of AIT equally takes into account both the severity of symptoms and the 101 
need for anti-allergic medication. A very important aim of this recommendation by international 102 
experts in AIT was to standardize the clinical endpoints of AIT trials internationally and, thereby, to 103 
improve the quality and comparability of AIT trials [9]. 104 
We have applied this principle to the UK22 trial [4] and reanalyzed the trial data post-hoc by 105 
calculating a composite score for symptoms and medication usage. In the UK22 trial nasal, eye 106 
and lung symptoms were recorded on daily diary cards using a 4-point scale (none, mild, 107 
moderate, severe) to assess the daily symptom score. The daily medication score had been 108 
weighted as sodium cromoglicate, 1 per drop; fluticasone nasal spray, 2 per puff; acrivastine (8 109 
mg), 2 per capsule; prednisolone (5 mg), 2 per tablet, salbutamol (100 µg), 1 per puff. For this 110 
post-hoc analysis the same data were used as for the primary analysis of the study, meaning that 111 
data were included from all subjects who had evaluable diary data (N=365, full analysis set) during 112 
the grass pollen season. A composite combined score was then calculated as the sum of the total   113 
daily symptom score and the total daily medication score averaged over the pollen season as 114 
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described above. The response variable was analyzed with a linear mixed effect (LME) model. 115 
More details on the statistical methods can be found in the online repository. 116 
The composite combined scores evaluated over the whole season in the reanalysis were 117 
significantly reduced compared with placebo (6.85 score points) both for the 100,000 SQ-U group 118 
(by 2.47 score points (p<0.0001) with a relative difference of 36.06% to Placebo), and for the 119 
10,000 SQ-U group (by 1.70 score points (p=0.0098) with a relative difference of 24.85% to 120 
Placebo), (Fig 1). These changes were not statistically different between the two immunotherapy 121 
groups.  122 
Thus, the relative differences of the composite combined score vs. placebo for both doses are of 123 
clinical relevance, according to the minimum criterion of ≥20% improvement recommended by 124 
WAO for judging the efficacy of allergy immunotherapy products [8]. The numerically larger clinical 125 
effect size of treatment with 100,000 SQ-U was associated with a higher frequency of adverse 126 
events compared to the 10,000 SQ-U dose [4]. This implies that it may be possible to use a 127 
patient-individualized treatment schedule, comparable to other pharmaceutical treatments for 128 
which different treatment doses are available. Patients could be up-dosed to a maintenance dose 129 
of 10,000 SQ-U for which a clinically relevant effect has been proven in this study. If patients 130 
remain unacceptably symptomatic during the first grass pollen season after start of AIT they could 131 
be considered to be further up-dosed to 100,000 SQ-U to achieve an increased clinical effect. With 132 
this approach it may be possible to achieve an optimal outcome for patients taking into account 133 
both tolerability and clinical effectiveness. 134 
The results of this post-hoc analysis confirm the main outcome of the UK22 trial as published 135 
previously [4] and additionally show that the lower maintenance dose of 10,000 SQ-U induces a 136 
clinically relevant effect in the first pollen season, after 5 to 8 pre-seasonal/seasonal maintenance 137 
injections. The importance of this post-hoc analysis is that it was performed in line with the 138 
recommendation of international experts to combine a symptom scoring together with a medication 139 
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scoring equally weighted for the analysis of the primary endpoint in field trials. Though the 140 
definition of the endpoint analyzed here slightly differs from the CSMS as recommended by the 141 
EAACI (as data from slightly modified symptom and medication domains were available for this 142 
analysis [9], see Table 2 in the Online repository), the demonstrated effect size indicates a better 143 
discrimination capability of a combined score compared to the individual symptom scores and 144 
medication scores as endpoints, as originally published [4]. This post-hoc analysis confirms earlier 145 
data showing that SQ®-standardized SCIT with Phleum pratense allergens with either 10,000 SQ-146 
U or 100,000 SQ-U was clinically effective in a phase III (field) trial.  147 
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Figure Legends 205 
Figure 1. Adjusted means of the composite endpoint combining symptom scores and medication 206 
scores in the reanalysis for placebo and active doses of 10,000 SQ-U and 100,000 SQ-U (whole 207 
grass pollen season), with relative differences between groups and 95% CI. All relative differences 208 
were statistically significant. Adj., Adjusted. 209 
 210 
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Supplementary data 1 
Details of statistical methods 2 
Treatment was handled as a fixed class effect and Region as a random class variable. 3 
Different residual errors for each treatment group were specified in the LME model. Each of the 4 
two active dose groups (100,000 SQ-U and 10,000 SQ-U) was compared to placebo using a t-test 5 
in the LME model. Adjusted means and the difference in adjusted means for each active dose 6 
group compared to placebo (placebo-active) were calculated together with the associated 95% 7 
confidence intervals. The relative differences of the adjusted means were also reported with 95% 8 
confidence limits, calculated based on Fieller’s theorem. 9 
 10 
Supplementary data on AIT product  11 
For Alutard SQ Phleum pratense long-term clinical efficacy has been demonstrated in a 12 
randomized, double blind, placebo-controlled long-term clinical trial for 3 years after 3 to 4 years of 13 
treatment with a maintenance dose of 100,000 SQ-U [1] with low risk of bias according to the 14 
recently published EAACI Guidelines on AIT in Allergic Rhinitis [2] and a 3-year randomized, 15 
double blind, placebo-controlled clinical trial [3]. 16 
A reduction of the risk of development of asthma in children with allergic rhinoconjunctivitis has 17 
been shown in an open randomized trial 7 years after discontinuation of a 3-year treatment with 18 
grass and/or birch allergens [4] with high risk of bias according to the EAACI Guidelines on AIT in 19 
Allergic Rhinitis and Allergy Prevention [2,5]. 20 
The efficacy of a maximum dose equivalent to 10,000 SQ-U (1,000 SE-U) has been demonstrated 21 
for the first pollen season after treatment in randomized double-blind placebo-controlled trials with 22 
an identically manufactured product (ALK7) containing grasses, rye [4] and tree allergens [5] with 23 
high quality and low risk of bias according to the EAACI Guidelines on AIT in Allergic Rhinitis [2].  24 
25 
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Supplementary Table 1. Subjective evaluation of treatment  26 
 27 
Subjects with ratings “better” or “a lot better” were used for calculation of responder rates according to [10]. 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 
100,000 SQ-U 
(N=203) 
n (%) 
10,000 SQ 
(N=104) 
n (%) 
Placebo 
(N=103) 
n (%) 
Overall 
(N=410) 
n (%) 
Number of subjects with an evaluation 180 (100.0) 89 (100.0) 91 (100.0) 360 (100.0) 
How has your hay fever been this year 
compared to previous years? 
    
a lot worse 0 2 (2.2) 3 (3.3) 5 (1.4) 
worse 1 (0.6) 0 2 (2.2) 3 (0.9) 
a little worse 3 (1.7) 1 (1.1) 1 (1.1) 5 (1.4) 
no change 8 (4.4) 10 (11.2) 16 (17.6) 34 (9.4) 
a little better 30 (16.7) 17 (19.1) 19 (20.9) 66 (18.3) 
better 44 (24.4) 24 (27.0) 24 (26.4) 92 (25.6) 
a lot better 94 (52.2) 35 (39.3) 26 (28.6) 155 (43.1) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
 40 
Supplementary Table 2. Symptom scores, medication scores and combined scores 41 
according to EAACI [8] /WAO [9] compared to the scores applied in reanalysis of UK22 42 
 43 
Scoring according to EAACI [8] Symptom 
score 
Scores applied in reanalysis of 
UK22  
Symptom 
score 
Nasal symptoms score 0-3 
(0=no, 1=mild, 
2=moderate, 
3=severe 
symptoms) 
Nasal symptoms score 0-3 
(0=no, 1=mild, 
2=moderate, 
3=severe 
symptoms) 
itchy nose 0-3 itchy nose 0-3 
sneezing 0-3 sneezing 0-3 
runny nose 0-3 runny nose 0-3 
blocked nose 0-3 blocked nose 0-3 
Conjunctival symptoms  Conjunctival symptoms 0-3 
itchy/red eyes 0-3 gritty feeling/red/itchy eyes 0-3 
watery eyes 0-3 watery eyes 0-3 
(Lung symptoms)*  Lung symptoms 0-3 
  cough 0-3 
  wheeze 0-3 
  tightness/dyspnea 0-3 
  exercised-induced symptoms 0-3 
Total daily symptom score (dSS) 0-3 (max. 
score is 3, i.e. 
18 points / 
divided by 6 
symptoms) 
Total daily symptom score (DSS) 0-30 (max. 
score is 30, 
sum of 10 
symptoms) 
Medication score  Medication score  
oral and/or topical (eyes or nose) 
nonsedative H1 antihistamines 
(H1A) 
1 sodium cromoglicate  1 per drop 
acrivastine (8mg) 2 per capsule 
intranasal corticosteroids (INS) 
with/without H1A 
2 fluticasone propionate nasal spray 2 per puff 
oral corticosteroids with/without 
INS, with without H1A 
3 prednisolone (5 mg) 2 per tablet 
  salbutamol (100µg) 1 per puff 
Total daily medication score (dMS) 0-3 Total daily medication score (DMS)  
Combined symptom and medication 
score 
 Combined symptom score and 
medication score 
 
CSMS = dSS (0-3) + dMS (0-3) 0-6 CS = DSS (0-30) + DMS  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
*according to WAO task force recommendation: “Bronchial symptoms must be included in patients 44 
with symptoms from the lower airways if a claim for asthma is requested for the trial.” [9] 45 
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